Efficacy of Aspirin and L-arginine in High Risk Preeclamptic
Status:
Suspended
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Worldwide, the incidence of preeclampsia ranges from 2 to 10% of pregnancies. The World
Health Organization (WHO) estimates that the incidence of preeclampsia is seven times higher
in developing countries than in developed (2.8% and 0.4%). In Mexico it is estimated that
preeclampsia - eclampsia is a major cause of maternal and perinatal morbidity and mortality.
Because it is an idiopathic heterogeneous syndrome associated with endothelial damage, so far
there is no effective treatment to decrease the morbidity and mortality of this entity, so it
is necessary to strengthen prevention; the use of aspirin alone is inconclusive, in addition
to the information the investigators have reduced the effect of these strategies on arterial
stiffness; Moreover, it has been observed that L-arginine lowers blood pressure in this
population. It is for this that is of interest to know the efficacy and safety of the
combination of L-arginine low dose, which is known as an important eNOS in NO production
substrate, and aspirin for its qualities of antiinflammatory and anticoagulant in the
prevention of preeclampsia and also determine their effect on arterial stiffness as a
noninvasive method, as is the applanation tonometry.
Phase:
Phase 2
Details
Lead Sponsor:
University of Guadalajara
Collaborators:
MD Diego Hernández Molina PhD Ernesto Javier Ramírez Lizardo PhD Fernando Grover Páez PhD Sylvia Elena Totsuka Sutto